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Summary
Tailored nanoparticles offer a novel approach to ﬁght
antibiotic-resistant microorganisms. We analysed
biogenic selenium nanoparticles (SeNPs) of bacterial
origin to determine their antimicrobial activity
against selected pathogens in their planktonic and
bioﬁlm states. SeNPs synthesized by Gram-negative
Stenotrophomonas maltophilia [Sm-SeNPs()] and
Gram-positive Bacillus mycoides [Bm-SeNPs(+)]
were active at low minimum inhibitory concentra-
tions against a number of clinical isolates of Pseu-
domonas aeruginosa but did not inhibit clinical
isolates of the yeast species Candida albicans and
C. parapsilosis. However, the SeNPs were able to
inhibit bioﬁlm formation and also to disaggregate the
mature glycocalyx in both P. aeruginosa and Can-
dida spp. The Sm-SeNPs() and Bm-SeNPs(+) both
achieved much stronger antimicrobial effects than
synthetic selenium nanoparticles (Ch-SeNPs). Den-
dritic cells and ﬁbroblasts exposed to Sm-SeNPs(),
Bm-SeNPs(+) and Ch-SeNPs did not show any loss
of cell viability, any increase in the release of reac-
tive oxygen species or any signiﬁcant increase in
the secretion of pro-inﬂammatory and immunostimu-
latory cytokines. Biogenic SeNPs therefore appear to
be reliable candidates for safe medical applications,
alone or in association with traditional antibiotics, to
inhibit the growth of clinical isolates of P. aerugi-
nosa or to facilitate the penetration of P. aeruginosa
and Candida spp. bioﬁlms by antimicrobial agents.
Introduction
Resistance to antimicrobial drugs has become more
widespread over the last decades resulting in a signiﬁ-
cant threat to public health. Infections caused by antibi-
otic-resistant bacteria need higher doses of drugs,
additional toxic treatments and extended hospital stays,
and ultimately result in increased mortality (Gadakh and
Van Aerschot, 2015). Despite the need for new antibi-
otics, only limited resources have been allocated by the
pharmaceutical industry to support the discovery of new
antibacterial agents, largely because the ﬁnancial returns
are likely to be small. To prevent or overcome antimicro-
bial resistance, non-antibiotic therapies will be necessary
to treat bacterial infections and alternative strategies that
show promise for the management of resistant infections
are already under investigation (Beyth et al., 2015; Gill
et al., 2015).
Most antibiotics that are active against free microbes
are less effective against the same species when pre-
sent as a bioﬁlm. This is a particular concern because
microbial bioﬁlms play a pivotal role in many infections,
and bioﬁlm-related traits may confer high-level antibiotic
resistance in microbial communities (Penesyan et al.,
2015). The bioﬁlm matrix can act as a mechanical bar-
rier, hindering the penetration of antibacterial agents and
immune response effectors. However, bacteria can also
become highly resistant to antibiotics as a result of nutri-
ent limitation or the emergence of a persistent but non-
growing phenotype that allows microbial cells to cope
efﬁciently with environmental stresses, including antibi-
otic challenge (Grant and Hung, 2013).
Strategies that prevent bioﬁlm formation or dispersal
are not fully effective in the absence of a treatment that
also counters the growth of individual cells. For this
reason, a combination of anti-bioﬁlm therapy along with
traditional antibiotics that target bacterial growth offers a
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promising approach for the control of bioﬁlm-related
infectious diseases. In such combination approaches,
the anti-bioﬁlm agent would force microbes into their
planktonic growth state, thus facilitating the targeting of
pathogens at the cellular level with traditional antibiotics
(Kostakioti et al., 2013).
Recent developments in nanotechnology allow the
production of tailored metal/metalloid nanoparticles with
physicochemical properties that can inhibit microorgan-
isms. These nanoparticles have been shown to over-
come existing drug resistance mechanisms, including
slow drug uptake and accelerated efﬂux, bioﬁlm forma-
tion and intracellular bacterial parasitism (Pelgrift and
Friedman, 2013). In this context, selenium nanoparticles
(SeNPs) possess antibacterial, antiviral and antioxidant
properties, suggesting they could be suitable as thera-
peutic candidates to combat infectious diseases. In par-
ticular, nanostructured particles can be synthesized
using bacterial and fungal cells as biological catalysts,
providing a non-toxic and environmentally beneﬁcial
approach for the production of nanoparticles, including
SeNPs (Xiangqian et al., 2011). Several microbial strains
can reduce the toxic selenite oxyanion to the less toxic
elemental selenium through the formation of either intra-
cellular or extracellular SeNPs, with a typical spherical
shape and a diameter of 50–400 nm (Lampis et al.,
2014). Furthermore, recent studies with biogenic SeNPs
have demonstrated that the particles have anti-bioﬁlm
activity against clinical isolates of bacterial pathogens
(Shakibaie et al., 2015). However, their antibacterial
effects are not fully understood and their potential toxicity
towards human tissues requires further investigation.
Another potential limitation affecting the clinical appli-
cation of metal/metalloid nanoparticles is the ability of
some nanostructured materials to stimulate the release,
by dendritic cells (DCs) and other cells in the immune
system, of reactive oxygen species and/or chemical
mediators that trigger unwanted side-effects such as
hypersensitivity reactions, autoimmune diseases and
inﬂammatory responses (Chang and Gershwin, 2010; Di
Gioacchino et al., 2011). In particular, activated DCs pro-
duce oxygen free radicals that can cause severe tissue
damage (Vulcano et al., 2004; Donini et al., 2007), and
may also release cytokines that play a key role in the
induction of inﬂammatory and immune responses (Elm-
quist et al., 1997; Suffredini et al., 1999; Granucci et al.,
2008; Sch€akel, 2009; Vignali and Kuchroo, 2012). There-
fore, nanoparticle candidates suitable for clinical applica-
tions must not induce DC activation or have toxic effects
against cells of the immune system and other tissues.
Here, SeNPs generated by two environmental bacterial
isolates, namely a strain of the Gram-positive species
Bacillus mycoides (Bm-SeNPs(+)) and a strain of the
Gram-negative species Stenotrophomonas maltophilia
(Sm-SeNPs()), were compared with chemically synthe-
sized SeNPs (Ch-SeNPs) in terms of their physical and
biological properties, including toxicity and immunostimu-
latory activity in vitro against cultures of human DCs and
ﬁbroblasts. The antibacterial and anti-bioﬁlm characteris-
tics of the SeNPs were tested against clinical strains of
Pseudomonas aeruginosa and clinical isolates of two
Candida species.
Results and discussion
Biosynthesis and characterization of SeNPs
Biogenic SeNPs were produced by exploiting the selen-
ite reduction capability of two different environmental
bacterial isolates, namely B. mycoides SeITE01 and
S. maltophilia SeITE02. The biogenic SeNPs were com-
pared with synthetic Ch-SeNPs in terms of their physico-
chemical characteristics. Scanning electron microscopy
(SEM) analysis indicated that all three SeNPs were
spherical and EDAX microanalysis of the puriﬁed SeNPs
revealed the characteristic selenium absorption peaks at
1.37 (SeLa), 11.22 (SeKa) and 12.49 keV (SeKb)
(Fig. 1). Moreover, SeNPs differently synthesized
showed different elemental composition (Table 1). For
instance, biogenic SeNPs showed a selenium percent-
age in weight of 11.01% and 9.26% for Sm-SeNPs()
and Bm-SeNPs(+) respectively. On the other hand, Ch-
SeNPs exhibited a higher percentage in selenium,
31.61%. Furthermore, the composition of biogenic
SeNPs, which were rich in C, O, P and S, suggests the
presence of biological macromolecules surrounding the
nanomaterials. Based on the presence and percentage
of C, O and S, it is possible to hypothesize that biogenic
SeNPs cap include proteins or enzymes and also some
cellular residues and membrane phospholipids (P
peaks). In particular, a tentative composition of the
biomolecular capping surrounding SeNPs biosynthesized
by S. maltophilia SeITE02 has been already reported.
Actually, Fourier transform infrared spectroscopy (FTIR)
analysis of Sm-SeNPs() evidenced the presence of
proteins, lipids and carbohydrates associated with the
nanomaterial (Lampis et al., 2016).
In Ch-SeNPs, the same elements are present in differ-
ent percentage: 60.91% in weight of C, 4.97% in weight
of O, 1.88% in weight of P and 0.63% in weight of S:
this is probably due to the procedure used for the syn-
thesis.
Dynamic light scattering measurements indicated aver-
age sizes of 170.6  35.12 nm for the Sm-SeNPs(),
160.6  52.24 nm for the Bm-SeNPs(+) and
102.5  29.44 nm for the Ch-SeNPs (Fig. 2).
All three SeNPs generated large negative zeta poten-
tials (between 70 and 80 mV) in solution (Fig. 2) sug-
gesting they are unlikely to form aggregates as a
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consequence of their electrostatic stability. Neutral and
negatively charged NPs tend to have long half-lives in
human serum and are not taken up by cells in a non-
speciﬁc manner (Alexis et al., 2008). This is important in
the context of potential in vivo applications as antimicro-
bial reagents.
Determination of the minimum inhibitory concentration
for SeNPs against Pseudomonas aeruginosa PAO1
In order to evaluate the effect of biogenic and synthetic
SeNPs as antimicrobial agents, as well as to study the
putative role of the biomolecular cap of the biogenic
nanoparticles, the determination of minimum inhibitory
concentration (MIC) values was ﬁrst carried out against
the reference strain Pseudomonas aeruginosa PAO1
(Table 2). MIC determination was carried out for the bio-
genic SeNPs, Sm-SeNPs() and Bm-SeNPs(+), the
chemically synthesized Ch-SeNPs, the Ch-SeNPs
exposed to cell free extract (CFX) of S. maltophilia
SeITE02 (CFX(Sm)-SeNPs) and B. mycoides SeITE01
(CFX(Bm)-SeNPs)) and CFX of S. maltophilia SeITE02
(CFX(Sm)) and B. mycoides SeITE01 (CFX(Bm)) alone.
As we can see from Table 2, Ch-SeNPs, Sm-SeNPs
() and Bm-SeNPs(+) evidenced a similar MIC value of
128 lg ml1. On the other hand, CFX(Sm)-SeNPs and
CFX(Bm)-SeNPs showed a lower activity towards the
reference strain, with a MIC value of 256 lg ml1.
Finally, CFX from both S. maltophilia SeITE02 and
B. mycoides SeITE01 did not exhibit antimicrobial activ-
ity at any of the concentration tested in the present anal-
ysis. These results clearly indicate that the antimicrobial
activity observed is exactly due to the nanoparticles and
the biomolecular cap to them associated through the
biosynthetic mechanism. Several studies have already
analysed the antimicrobial activity of SeNPs synthesized
chemically towards different pathogenic bacterial strains.
For instance, chemically synthesized SeNPs were able
to inhibit the growth of Staphylococcus aureus (Tran and
Webster, 2011), with higher efﬁciency than silver phos-
phate nanoparticles (Chudobova et al., 2014).
Antimicrobial activity of SeNPs against clinical isolates of
P. aeruginosa and Candida spp.
To test the antibacterial and anti-bioﬁlm activity of the
SeNPs, we selected a series of clinical strains of
P. aeruginosa, whose surrounding polysaccharide bioﬁlm
(I) (II)
(III)
(IV)
Fig. 1. Scanning electron microscopy analysis of SeNPs produced by Stenotrophomonas maltophilia SeITE02 (I), SeNPs produced by Bacillus
mycoides SeITE01 (II) and chemically synthesized SeNPs (III). EDX analysis of biogenic SeNPs (IV).
Table 1. Elemental composition of Ch-SeNPs, Sm-SeNPs() and
Bm-SeNPs(+) calculated through EDX analysis.
Element Ch-SeNPs Sm-SeNPs() Bm-SeNPs(+)
C 60.91 73.13 75.75
O 4.97 10.44 10.82
Se 31.61 11.01 9.26
P 1.88 4.42 3.14
S 0.63 1.00 1.04
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matrix confers resistance to eradication by antibiotics
and clearance by the immune system. Such strains are
recurrent in the chronic lung infections that characterize
cystic ﬁbrosis, chronic obstructive pulmonary disease
and asthma (Ciofu et al., 2015). The multidrug-resistant
isolate P. aeruginosa INT was chosen to provide a
Fig. 2. Dynamic light scattering analysis and zeta potential of SeNPs produced by Stenotrophomonas maltophilia SeITE02 (I), SeNPs produced
by Bacillus mycoides SeITE01 (II) and chemically synthesized SeNPs (III).
Table 2. Minimum inhibitory concentration (MIC) of Ch-SeNPs, Ch2-SeNPs, Sm-SeNPs(), Bm-SeNPs(+), CFX(Sm)-SeNPs, CFX(Bm)-SeNPs,
CFX(Sm) and CFX(Bm) against Pseudomonas aeruginosa PAO1.
Strain
Ch-SeNPs
MIC
(lg ml1)
Ch2-SeNPs
MIC
(lg ml1)
Sm-SeNPs()
MIC
(lg ml1)
Bm-SeNPs(+)
MIC
(lg ml1)
CFX(Sm)-
SeNPs
MIC (lg ml1)
CFX(Bm)-
SeNPs
MIC (lg ml1)
CFX(Sm)
MIC
(ll ml1)
CFX(Bm)
MIC
(ll ml1)
Pseudomonas
aeruginosa
PAO1
128 128 128 128 256 256 >512 >512
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particularly challenging target, whereas P. aeruginosa
PA01 and ATCC 27853 were included as reference
strains. The ability of SeNPs to inhibit bacterial growth
was tested by challenging the bacterial isolates and ref-
erence strains with different concentrations of SeNPs,
then determining the MIC using the agar well diffusion
assay and the broth dilution method.
As shown in Table 3, the MIC of Sm-SeNPs() varied
widely among the different P. aeruginosa strains, ranging
from 8 to 16 lg ml1 in strains isolated from low respira-
tory tract infections (CFC20, CFC21, CFCA and CFCB)
to 128–512 lg ml1 against P. aeruginosa INT and both
the reference strains. The MIC of Bm-SeNPs(+) also var-
ied among the strains but was generally 2–4 times
higher than Sm-SeNPs (Table 3). The MIC of Ch-SeNPs
indicated that these SeNPs have no effect on the growth
of P. aeruginosa (Table 3).
The susceptibility of the reference strains P. aerugi-
nosa PAO1 and ATCC 27853 to Sm-SeNPs() was
determined in a previous study and the reported MIC
values were slightly different to those we observed
(250 lg ml1) (Zonaro et al., 2015). The difference prob-
ably reﬂects the distinct methods used to determine the
MIC in each study and the use of different growth media,
which is known to affect the toxicity of NPs (Loza et al.,
2014).
We found that P. aeruginosa clinical strains CFC20,
CFC21, CFCA and CFCB were susceptible to Sm-SeNPs
with MIC values in the range 2.5–20 lg ml1, which is
broadly in agreement with previous reports dealing with
other nanoparticles (Habash et al., 2014; Tomita et al.,
2014). Because these MIC values fall within the range of
clinical exposures adopted during typical antibiotic treat-
ments, biogenic SeNPs could be used to treat antibiotic-
resistant clinical strains, eventually overcoming the poten-
tial risks of antibiotic resistance (Table 3). Our analysis of
antibiotic susceptibility carried out according to Clinical
and Laboratory Standards Institute standard methods
(Jorgensen and Ferraro, 2009) demonstrated that the four
P. aeruginosa clinical strains were resistant to beta-lac-
tams (MIC values varying between 16 and ≥ 64 lg ml1)
and other antibiotics such as gentamicin (MIC values 8–
16 lg ml1), ciproﬂoxacin (MICs between 2 and
≥ 4 lg ml1) and sulphonamides (MIC values
40–80 lg ml1).
Conversely, given the much higher MIC for P. aerugi-
nosa INT (> 250 lg ml1) compared with the clinical
strains, it is unlikely that SeNPs could solve the problem
of antibiotic resistance in this isolate.
We also evaluated the anti-fungal activity of SeNPs by
testing in vitro their ability to inhibit the growth of C. albi-
cans and C. parapsilosis clinical strains. The MIC values
were very high (> 256 lg ml1) indicating that SeNPs do
not inhibit the growth of these yeast strains.
Inhibition of P. aeruginosa and Candida spp. bioﬁlm
formation by SeNPs
To analyse the effect of SeNPs on bioﬁlm synthesis, the
P. aeruginosa strains and the two Candida species were
treated for 48 h at 37°C with different concentrations of
Bm-SeNPs(+), Sm-SeNPs() and Ch-SeNPs, and bio-
ﬁlm formation was quantiﬁed by methylene blue staining.
The percentage of bioﬁlm inhibition was calculated by
comparing the microbial cultures exposed to the SeNPs
with the same strains growing in the absence of SeNPs.
The quantity of bioﬁlm produced by P. aeruginosa
strains CFCA and CFCB was greater than that produced
by the other P. aeruginosa strains and by the yeast iso-
lates, when values were averaged over six experiments
(Table 4). The lowest concentrations of biogenic SeNPs
(50 and 100 lg ml1) inhibited bioﬁlm synthesis by
P. aeruginosa strains CFC20, CFC21 and CFCA by 70–
90%, indicating that they are particularly sensitive to the
SeNPs. In contrast, clinical strains CFCB and INT, as
well as the reference strains, were more resistant to the
SeNPs, showing the signiﬁcant inhibition of bioﬁlm syn-
thesis (at least 70%) only in the presence of SeNP con-
centrations ≥ 250 lg ml1. Table 4 also shows that Sm-
SeNPs() were usually more potent than Bm-SeNPs(+),
and that the synthetic Ch-SeNPs were only active at
concentrations of 250–500 lg ml1 against most strains,
the exception being P. aeruginosa CFC20, which was
the most susceptible isolate tested.
Interestingly, the lowest SeNP dose we tested
(50 lg ml1) was sufﬁcient for 60–70% bioﬁlm inhibition
in the two yeast isolates, and no signiﬁcant improvement
was achieved at the higher doses of 100 and
250 lg ml1 (Table 5). Sm-SeNPs() and Bm-SeNPs(+)
had similar effects on bioﬁlm formation in the yeast
Table 3. Minimal inhibitory concentrations (MICs) for Stenotropho-
monas maltophilia (Sm)-SeNPs, Bacillus mycoides (Bm)-SeNPs and
chemically synthesized (Ch)-SeNPs tested against different micro-
bial strains isolated from clinical samples. MIC values in the clinical
usage range are in bold.
Bacterial strain/Candida
species
MIC (lg ml1)
Sm-SeNPs Bm-SeNPs Ch-SeNPs
Pseudomonas aeruginosa
PAO1
128 128 128
P. aeruginosa ATCC27853 512 512 >512
P. aeruginosa INT 256 512 >512
P. aeruginosa CFC20 16 64 128
P. aeruginosa CFC21 8 32 128
P. aeruginosa CFCB 16 32 >128
P. aeruginosa CFCA 16 64 >128
Candida albicans 256 512 >512
C. parapsilosis 512 512 >512
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strains, whereas the Ch-SeNPs had no signiﬁcant effect
(Table 5). Previous investigation on the anti-fungal effect
of biogenic SeNPs synthesized by Klebsiella pneumo-
niae on C. albicans strain TUMS R152 showed a MIC of
2000 lg ml1 (Kazempour et al., 2013), a value higher
than the concentrations tested in this analysis. Contrarily
to recent results evidencing a clear anti-fungal activity of
nanoparticles of different metals obtained by chemical
synthesis (Lara et al., 2015), chemically synthesized
SeNPs, although capable of antimicrobial activity against
a number of nosocomial bacterial pathogens, were not
efﬁcacious towards the pathogenic yeasts tested, namely
C. albicans and C. parapsilosis. In the present study,
proteins associated to SeNPs of biogenic nature (Wang
et al., 2010) apparently played a role in the anti-fungal
activity against yeasts that seemed — on the other hand
— not to be affected by chemically synthesized SeNPs.
The anti-fungal activity of the biogenic SeNPs assayed
was probably due to the disruptive interaction of their
organic coat with the yeast outer wall layer, containing in
Candida sp. mainly mannans and phosphorylated man-
nans. Permeabilization of the cell wall and subsequent
disaggregation of the structural layers of the outer fungal
cell wall are likely to be occurred. Nevertheless, the toxi-
city of metal nanoparticles towards yeasts and the asso-
ciated toxic mechanisms remain controversial, and
further investigation is needed in this area. Particularly,
the cell wall constitutes the primary site for direct interac-
tion with nanoparticles. Changes in yeast cell wall struc-
ture have been reported in response to many factors,
e.g. growth conditions, mode of cultivation, compounds
that block cell wall synthesis and anti-fungal substances.
However, there is a lack of information concerning
changes in the cell wall composition in response to
nanoparticle exposure (Sun et al., 2014).
Degradation of P. aeruginosa and Candida spp. bioﬁlms
by SeNPs
We next investigated whether the SeNPs were able to
cause the degradation of bioﬁlms by measuring the
amount of bioﬁlm remaining after exposing the synthe-
sized exopolysaccharide to different concentrations of
biogenic and synthetic SeNPs (Table 6 and Table 7).
The P. aeruginosa CFC20 bioﬁlm was highly susceptible
to SeNP-induced disaggregation, resulting in 90% degra-
dation in the presence of 50 lg ml1 SeNPs, conﬁrming
that this strain is more susceptible to SeNPs than the
other strains. The exposure of the other P. aeruginosa
strains to 50–100 lg ml1 SeNPs resulted in 50–70%
bioﬁlm degradation, and this did not increase at higher
SeNP concentrations. Sm-SeNPs() were slightly more
efﬁcient than Bm-SeNPs(+) in the eradication of
P. aeruginosa bioﬁlms. Similarly, the biogenic SeNPsTa
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eradicated 45–60% of the yeast bioﬁlms at the lowest
SeNP doses (50–100 lg ml1) and there was no
improvement at higher doses. There was no signiﬁcant
difference in efﬁcacy between the two types of biogenic
SeNPs.
The comparison of SeNPs from different origins pro-
vides insights into the optimization of strategies to inhibit
the synthesis of bioﬁlms or destroy bioﬁlms that already
exist. Biogenic SeNPs at concentrations of 50–
100 ll ml1 can suppress the synthesis of bioﬁlms in
three of the ﬁve clinical isolates of P. aeruginosa we
tested, as well as two Candida species. SeNPs synthe-
sized by the Gram-negative bacterium S. maltophilia
SeITE02 were slightly more efﬁcacious than those pro-
duced by the Gram-positive species B. mycoides
SeITE01, although at concentrations ≥ 250 lg ml1 both
SeNPs were remarkably potent. Nevertheless, different
clinical isolates of P. aeruginosa varied in susceptibility
at physiologically compatible concentrations of biogenic
SeNPs. The most potent disaggregation effects (45–
70%) against both P. aeruginosa and yeast were
observed at a SeNP concentration of 100 lg ml1, and
higher doses did not achieve greater activity. The disag-
gregation of P. aeruginosa bioﬁlms by SeNPs also
showed strain-dependent efﬁcacy, with strain CFC20
appearing particularly susceptible to bioﬁlm disintegration
probably due to the synthesis of a fragile exopolysaccha-
ride matrix compared with the tougher and physically
more resistant exopolysaccharide formations of the other
isolates. Generally, the biogenic SeNPs at concentra-
tions of 50–100 lg ml1 (and the Sm-SeNPs() in par-
ticular) were more effective in the destruction of existing
bioﬁlm structures than the inhibition of bioﬁlm synthesis.
This suggests that the anti-bioﬁlm mechanism of these
nanomaterials is possibly targeted to a component of the
mature bioﬁlm structure. The biogenic SeNPs were more
effective than synthetic counterparts, indicating that
organic molecules on the surface are likely to contribute
to their antimicrobial activities and enhance the effect of
the inorganic selenium component.
Effects of SeNPs on human cells
Some nanoparticles are known to be cytotoxic or to stim-
ulate human cells, resulting in harmful off-target effects
(Chang and Gershwin, 2010; Di Gioacchino et al.,
2011). The biogenic SeNPs in this study contain organic
substances of bacterial origin, so it is necessary to
determine whether they can damage human cells, or
stimulate unanticipated effects, in the latter case particu-
larly in immune system cells that recognize foreign struc-
tures and respond in order to neutralize and eliminate
pathogens. We therefore investigated whether Sm-
SeNPs() and Bm-SeNPs(+), as well as Ch-SeNPs
lacking biogenic molecules, affected the viability and
activity of DCs. These are immune system cells that are
fundamentally involved in the orchestration of inﬂamma-
tory and immune response (Granucci et al., 2008;
Sch€akel, 2009). Human blood monocytes were cultured
for 5 days in the presence of GM-CSF and interleukin 4
(IL-4) to obtain DCs, which were then challenged with
different doses of SeNPs or with the bacterial immunos-
timulator LPS as a positive control. We also analysed
the effect of SeNPs on the viability and activity of cul-
tured human ﬁbroblasts to determine whether SeNPs
have adverse effects on non-immune cells. Cell viability
was assessed using Alamar blue, a colorimetric redox
assay of metabolic activity. Different concentrations of
the biogenic SeNPs (and Ch-SeNPs) did not induce
apoptosis in cultured DCs or ﬁbroblasts, even at the
highest dose of 500 lg ml1, which is atypically high for
standard in vitro cell stimulation protocols (Fig. 3).
We then investigated whether SeNPs stimulate DCs
to release of pro-inﬂammatory and immunostimulatory
cytokines (particularly those involved in the activation of
inﬂammatory and immune responses), such as IL-12
which stimulates natural killer cells and T lymphocytes
(Vignali and Kuchroo, 2012), IL-8 which causes leuco-
cyte chemotaxis and activation (Admyre et al., 2015), as
well as IL-6 and TNF-a which elicit inﬂammation and the
systemic acute phase reaction, characterized by fever,
Table 5. Percentage of bioﬁlm synthesis inhibition in different fungal strains caused by Sm-SeNPs, Bm-SeNPs and Ch-SeNPs.
15 30 50 60 100 120 250 325 400 500
Sm-SeNPs () lg ml1
Candida albicans 40  0.7 45  0.5 61  0.5 59  0.7 60  3 69  1 60  1 65  2 77  1 94  1
C. parapsilosis 9  3 42  1 72  1.5 60  1.5 79  0.5 70  1 73  1 72  1 79  3 95  1
Bm-SeNPs() lg ml1
C. albicans 51  2 55  2 60  6.5 63  3 69  2 68  2 74  2.5 74  1.5 82  0.5 93  0.5
C. parapsilosis 33  2 49  1 75  1.5 70  2.5 73  0.5 70  2 72  3 71  2 77  1.5 94  0.5
Ch-SeNPs() lg ml1
C. albicans 0 0 0 0 0 0 0 0 5  0.9 9  0.7
C. parapsilosis 0 0 0 0 0 0 0 0 4  1 5  0.7
The percentage of inhibition was calculated relative to the quantity of bioﬁlm formed by each strain in the absence of nanoparticles. Data are
the average of results obtained in three different experiments. Percentages of inhibition higher than 80% are shown in bold.
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headache, anorexia, nausea, emesis and changes in the
sleep–wake cycle (Elmquist et al., 1997; Suffredini et al.,
1999).
The analysis of DC culture supernatants by enzyme-
linked immunosorbent assay (ELISA) revealed that
SeNPs did not induce a signiﬁcant increase in the
release of IL-12, IL-6, IL-8 or tumor necrosis factor alpha
(TNF-a) until the doses reached 250–500 lg ml1, which
are unlikely to be achieved in vivo (Fig. 4). Cytokine
release was stimulated more efﬁciently when DCs were
challenged with Sm-SeNPs() rather than Bm-SeNPs
(+), but bacterial LPS had a much more potent effect.
Interestingly, the synthetic SeNPs did not induce the
release of cytokines at any dose, suggesting that inor-
ganic selenium is unable to stimulate human DCs alone
and that organic molecules on the surface of biogenic
SeNPs must be responsible for the observed effect. The
identity of these organic molecules will be the subject of
future research. We also explored whether SeNPs inﬂu-
ence the release of pro-inﬂammatory cytokines by
human ﬁbroblasts. We found that neither the biogenic
SeNPs nor the Ch-SeNPs induced the secretion of IL-8,
IL-6 or TNF-a by ﬁbroblasts (data not shown), whereas
1 lg ml1 LPS as a positive control induced human
ﬁbroblasts to secrete all three of these cytokines (data
not shown).
Activated human DCs can also release remarkable
quantities of reactive oxygen species that cause oxida-
tive damage to neighbouring cells (Vulcano et al., 2004;
Donini et al., 2007). We therefore investigated whether
SeNPs were able to induce human DCs to produce oxy-
gen radicals using the cytochrome c reaction assay to
measure the quantity of superoxide anion release by the
cells (Vulcano et al., 2004). We found that neither the
biogenic SeNPs nor the Ch-SeNPs induced the release
of superoxide anions by DCs, whereas microbial cell wall
glucan, which is known to promote the release of super-
oxide anions by immune system cells (Gantner et al.,
2003; Donini et al., 2007) was able to achieve this effect
(data not shown). Collectively, our results demonstrate
that although SeNPs inhibit bacterial growth, they are
unable to cause signiﬁcant damage to human DCs and
ﬁbroblasts or to stimulate the release of cytokines or
reactive oxygen species from the same cells, making
them suitable candidates for further development as
in vivo antimicrobial reagents.
Conclusions
We have demonstrated that SeNPs synthesized by both
B. mycoides SeITE01 and S. maltophilia SeITE02 pos-
sess potent antibacterial activities with low MIC values
against a number of clinical strains of P. aeruginosa, but
no biocidal effects against two clinical isolates ofTa
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Table 7. Percentages of bioﬁlm degradation in different fungal strains caused by Sm-SeNPs, Bm-SeNPs and Ch-SeNPs.
15 30 50 60 100 120 250 325 400 500
Sm-SeNPs() lg ml1
Candida albicans 0 5  0.5 26  2.5 30  1 43  2.5 30  1.4 47  3.5 49  2 55  3 60  2
C. parapsilosis 0 0 52  2 48  1.4 48  1.5 43  1.5 48  2.5 50  0.5 59  2.5 64  2
Bm-SeNPs() lg ml1
C. albicans 0 0 11  2.5 12  2 32  2 41  2 48  1.5 51  2 61  1 60  3.5
C. parapsilosis 0 0 48  3 42  1.5 38  2 43  1.5 47  2 44  1.5 47  2 42  2.5
Ch-SeNPs() lg ml1
C. albicans 0 0 0 0 0 0 2 0 0 0
C. parapsilosis 0 0 0 0 1 0 0 0 0 0
The percentage of degradation was calculated relative to the quantity of bioﬁlm formed by each strain in the absence of nanoparticles. Data rep-
resent the means of three different experiments.
Fig. 3. Evaluation of cell viability. DCs (I) and ﬁbroblasts (II) were treated with the indicated concentrations of Sm-SeNPs(), Bm-SeNPs(+) or
Ch-SeNPs for 24 h, followed by 4-h incubation with Alamar blue. Cells were also incubated with 100 ng ml1 LPS as a positive control. The
values are expressed as the percentage of Alamar blue reduction relative to untreated cells (designated as 100%). Data are means  SD of
four experiments.
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C. albicans and C. parapsilosis. To the best of our
knowledge, this is the ﬁrst report conﬁrming that biogenic
SeNPs are potentially suitable as antimicrobial agents
against clinical strains isolated from patients with chronic
lung diseases. We also show that the biogenic SeNPs
can inhibit bioﬁlm synthesis by P. aeruginosa and the
two Candida species, and can efﬁciently disaggregate
the mature exopolysaccharide matrix produced by these
microorganisms. The antimicrobial potential of these bio-
genic SeNPs is greater than that of synthetic SeNPs,
probably due to the presence of a bacterial protein layer
coating the surface of the biogenic particles. Further-
more, SeNPs produced by the Gram-negative species
S. maltophilia are more potent antibacterial agents than
those produced by the Gram-positive species B. my-
coides, suggesting that SeNPs with similar dimensions
but originating from taxonomically distinct bacterial
strains may show different activities, probably due to the
different composition of their organic surface layer.
Finally, neither the biogenic nor the synthetic SeNPs
affected the viability of human DCs and ﬁbroblasts, nor
did they elicit the production of reactive oxygen species
or the substantial secretion of pro-inﬂammatory and
immunostimulatory cytokines. Our data therefore suggest
that the biogenic SeNPs are biocompatible structures that
could be administered, either alone or in combination with
antibiotics, in new therapeutic strategies to inhibit the
growth of pathogens, including those resistant to antibi-
otics, or to facilitate the penetration of microbial bioﬁlms.
Experimental procedures
Reagents
Analytical grade sodium selenite, selenous acid and
reagents used for the chemical synthesis of SeNPs were
purchased from Sigma-Aldrich (Milan, Italy). RPMI 1640,
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and L-glu-
tamine were obtained from Lonza (Walkersville, MD,
USA). Recombinant human GM-CSF and human IL-4
were purchased from Miltenyi Biotec GmbH (Bergisch
Gladbach, Germany). Low-endotoxin FBS and Saccha-
romyces cerevisiae glucan were obtained from Sigma-
Aldrich. All of the above reagents contained less than
0.125 endotoxin units per mL, as determined by the
Fig. 4. Quantiﬁcation of cytokine production. DCs were challenged with the indicated amounts of Sm-SeNPs(), Bm-SeNPs(+) or Ch-SeNPs
for 24 h. DCs were also activated with 100 ng ml1 LPS as a positive control. The release of the indicated cytokines into the culture super-
natants was evaluated by ELISA. The results are expressed as the mean value  SD of three independent experiments. Statistical analysis:
SeNP-treated DCs versus untreated cells *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Limulus amebocyte lysate assay (Microbiological Associ-
ates, Walkersville, MD, USA). Ultrapure lipopolysaccha-
ride (LPS 0111, B4 strain) from Escherichia coli was
purchased from InvivoGen (San Diego, CA, USA). Mouse
anti-human CD1a (HI149) antibody was obtained from
Becton–Dickinson (San Jose, CA, USA).
Preparation of SeNPs
Two environmental isolates (Gram-positive B. mycoides
SeITE01 and the Gram-negative S. maltophilia SeITE02)
were used to produce the biogenic Bm-SeNPs(+) and
Sm-SeNPs() respectively (Di Gregorio et al., 2005;
Lampis et al., 2014). Sterile nutrient broth supplemented
with 2 mM Na2SeO3 was inoculated to achieve ﬁnal con-
centrations of 105 and 107 CFU ml1 for B. mycoides
SeITE01 and S. maltophilia SeITE02 respectively. The
cultures were incubated aerobically at 27°C in a rotary
shaker (150 r.p.m.) for 6 h (B. mycoides SeITE01) or
24 h (S. maltophilia SeITE02). Bacterial cells and
nanoparticles were removed from the culture medium by
centrifugation at 10 000 g for 10 min. The pellets were
washed twice with 0.9% NaCl, suspended in Tris/HCl
buffer (pH 8.2) and the cells were disrupted by ultrasoni-
cation at 100 W for 5 min. The suspension was then
centrifuged at 10 000 g for 30 min to separate disrupted
cells (pellet) from nanoparticles (supernatant). The
nanoparticles were recovered after centrifugation at
40 000 g for 30 min, washed twice and suspended in
deionized sterile water. Ch-SeNPs were produced as
described by Lin and Wang (2005), while Ch2-SeNPs
were produced as described by Li et al. (2010).
Cell free extracts and CFX-SeNPs preparation
Stenotrophomonas maltophilia SeITE02 and B. my-
coides SeITE01 cells were grown for 24 h until station-
ary phase. They were then centrifuged at 3000 g for
15 min and washed twice with phosphate buffer saline.
The pellet was resuspended in 100 mM Tris–HCl pH 7.4
and sonicated at 100 W ﬁve times for 5 min. Finally,
unbroken cells were separated by centrifugation at
16 000 g for 30 min and the supernatant was recovered.
CFX-SeNPs were then prepared by exposing Ch-
SeNPs to CFX of S. maltophilia SeITE02 or B. mycoides
SeITE01 overnight in agitation. CFX-SeNPs were recov-
ered through centrifugation and washed twice with
100 mM Tris–HCl pH 7.4, as described by Dobias and
coworkers (Dobias et al., 2011).
Scanning electron microscopy
Both the biogenic and synthetic SeNPs were analysed
by SEM. The nanoparticles were ﬁxed, dehydrated
through an increasing ethanol concentration series and
dried in liquid CO2 using the critical point method. The
particles were mounted on metallic specimen stubs and
directly observed using an XL30 ESEM (FEI, Hillsboro,
OR, USA) equipped with an EDAX micro-analytical sys-
tem, which was used to determine the elemental compo-
sition of the analysed nanoparticles.
Dynamic light scattering
Dynamic light scattering analysis was carried out using a
Zen 3600 Zetasizer Nano ZS (Malvern Instruments, Mal-
vern, UK) equipped with a 633 nm helium–neon laser
light source (4.0 mW), detecting scattering information at
a ﬁxed angle of 173°. Samples (300 ll) were transferred
to a quartz cuvette (10 mm path length), and the mean
size distribution and zeta potential were recorded at
25°C using the software provided by Malvern Instru-
ments.
Microbial strains and growth conditions
We used ﬁve P. aeruginosa clinical strains (INT, CFC20,
CFC21, CFCA and CFCB) and two reference strains
(PAO1 and PYO27853). P. aeruginosa INT is a mul-
tidrug-resistant strain isolated from a urinary tract infec-
tion and it carries the class 1 integron containing
multiple antibiotic-resistant gene cassettes. Strains
CFC20, CFC21, CFCB and CFCA were isolated from
the sputum of patients from the Cystic Fibrosis Center of
Verona, following the provision of written informed con-
sent from the subjects enrolled in the study.
The bacterial strains were grown in tryptic soy broth
(TSB) (Difco Laboratories, Detroit, MI, USA) or TSB
medium supplemented with 1% glucose (TSB-1% glu-
cose).
Two yeast clinical strains, Candida albicans CVr-21
and Candida parapsilosis CPVr-5, isolated from vaginal
swabs, were also included in the study and grown in
Sabouraud medium. Cell growth was monitored with a
LKB spectrophotometer at 640 nm (OD640nm).
Nanoparticle susceptibility assay
The MIC of the different types of SeNPs tested (Ch-
SeNPs, Ch2-SeNP, Sm-SeNPs(), Bm-SeNPs(+), CFX
(Sm)-SeNPs, CFX(Bm)-SeNPs) and cell free extracts
(CFX(Sm) and CFX(Bm)) was ﬁrst measured against the
reference strain P. aeruginosa PAO1.
Afterwards, MICs were determined by the broth
microdilution method (National Committee for Clinical
Laboratory Standards, 2010) and were used to evaluate
the susceptibility of the microbial strains. The susceptibil-
ity of the strains was conﬁrmed in an agar diffusion
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assay by monitoring for the presence or absence of a
bacterial growth inhibition halo surrounding wells con-
taining different concentrations of SeNPs.
Bioﬁlm formation assay
Bacterial cells were grown at 37°C in TSB-1% glucose
and yeast cells were grown in Sabouraud medium until
in each case they reached the exponential growth phase
(OD650nm = 0.4). Cells were then diluted in TSB-1% glu-
cose or Sabouraud medium to reach ~106 CFU ml1.
We then inoculated sterile ﬂat-bottomed polystyrene
CytoOne microtiter plates (Starlab, Milan, Italy) with
200 ll of each cell suspension or 200 ll of the medium
without cells as a negative control. The anti-bioﬁlm prop-
erties of SeNPs were investigated by diluting them in
growth medium to concentrations of 50, 100, 250 and
500 lg ml1, and adding them to the microtiter wells.
The plates were incubated aerobically at 37°C without
agitation for 48 h to allow bioﬁlm formation. After incuba-
tion, the planktonic cells and the growth medium were
aseptically aspirated and the bioﬁlm matrix washed with
sterile saline solution and dried. Bioﬁlm quantiﬁcation
was carried out by adding 100 ll of 1% methylene blue
to each well and incubating for 15 min at room tempera-
ture. The wells were then slowly washed with sterile
water and dried at 37°C. The methylene blue bound to
the bioﬁlm was extracted in 100 ll 70% ethanol and the
absorbance was measured at 570 nm using an A3
Plate Reader (DAS, Rome, Italy). All experiments were
performed in triplicate. Optical densities greater than 2,
between 1 and 2 or between 0.5 and 1 optical units
were considered to correspond to strong (S), medium
(M) or low (L) bioﬁlm production respectively.
Bioﬁlm disaggregation assay
Bioﬁlm disaggregation triggered by SeNPs was mea-
sured by seeding the microbial suspensions into 96-well
microplates and incubating at 37°C to allow bioﬁlm for-
mation. After 48 h, the medium was aseptically aspi-
rated. SeNPs were diluted in growth medium to
concentrations of 50, 100, 250 and 500 lg ml1, and
were added to the wells. The prepared microplates were
then incubated for 24 h at 37°C and the amount of bio-
ﬁlm was quantiﬁed as described above. All experiments
were performed in triplicate.
Preparation and culture of dendritic cells
After written informed consent was received from donors,
and approval by the Ethical Committee (Prot. no. 5626,
February 2nd 2012, and Prot. no. 43318, September 4th
2013), buffy coats from the venous blood of normal
healthy volunteers were obtained from the Blood Trans-
fusion Centre at the University Hospital of Verona.
Peripheral blood mononuclear cells were isolated by
Ficoll-Hypaque and Percoll density gradient centrifuga-
tion (GE Healthcare Life Sciences, Little Chalfont, UK)
and used for the immunomagnetic isolation (Miltenyi Bio-
tec) of CD14+ cells as previously described (Zenaro
et al., 2009). DCs were isolated by incubating 1 9 106
monocytes per ml at 37°C in 5% CO2 for 5–6 days in
six-well tissue culture plates (Greiner Bio-One, N€urtin-
gen, Germany) in RPMI 1640 medium supplemented
with heat-inactivated 10% low-endotoxin FBS, 2 mM L-
glutamine, 50 ng ml1 GM-CSF and 20 ng ml1 IL-4.
The ﬁnal DC population was 98% CD1a+, as measured
by FACS analysis.
Culture of ﬁbroblasts
Human primary ﬁbroblast CCD1112Sk cells (ATCC
CRL-2429) were purchased from ATCC (Manassas, VA,
USA) and cultured in DMEM supplemented with 10%
heat-inactivated FBS plus 2 mM L-glutamine at 37°C in
5% CO2.
Quantiﬁcation of cytokine production
Cytokine production in cell culture supernatants was
determined by ELISA using Ready-Set-Go ELISA kits
(eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. We measured the levels of
IL-12 (range 4–500 pg ml1), TNF-a (range 4–
500 pg ml1) and IL-6 (range 2–200 pg ml1). The
ELISA development kit (Mabtech, Nacka Strand, Swe-
den) was used to determine the level of IL-8 (CXCL8
range 4–400 pg ml1). Brieﬂy, DCs were treated with dif-
ferent concentrations of SeNPs for 24 h, and then the
supernatants were collected. DCs were also activated
with 100 ng ml1 LPS as a positive control. The plates
were read at 450 nm with Victor3 1420 Multilabel Coun-
ter (Perkin Elmer, Waltham, MA, USA).
Cell viability evaluation
Cell viability was assessed using the AlamarBlue assay
(Invitrogen, Thermo Fischer Scientiﬁc, Waltham, MA,
USA) according to the manufacturer’s instructions. After
incubation for 24 h with SeNPs, the reagent was added
to the culture medium a ﬁnal concentration of 10%
before measuring the absorbance at 570 and 600 nm.
Superoxide anion production
The release of O2
 was estimated by cytochrome c
reduction as previously described (Vulcano et al., 2004).
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Brieﬂy, after cell culture, the medium was replaced with
HBSS (pH 7.4) containing 80 lM ferricytochrome c
(Sigma-Aldrich) and the required stimulus. Cytochrome c
reduction was determined by measuring absorbance at
550 nm using a Perkin-Elmer Victor3 1420 Multilabel
Counter.
Statistical analysis
Data are presented as means plus standard deviations.
Statistical analysis, including two-way analysis of vari-
ance, was carried out using GraphPad Prism v6.0
(GraphPad Software Inc., La Jolla, CA, USA).
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